Liofilchem AD Fosfomycin panel comprises 12 wells, with antibiotic incorporated into an agar medium in 11 two-fold dilutions (0.25-256 μg/mL)
With an increase in the numbers of bacterial isolates resistant to first-line antibiotics, there has been a revival in the use of older drugs including fosfomycin. Although several commercial tests based on different techniques have been developed, Agar Dilution (AD) is considered the best method for performing Fosfomycin susceptibility testing so far.
The new AD Fosfomycin 0.25-256 is the first and only (international patent pending) ready-to-use commercially available kit for performing the agar dilution antimicrobial susceptibility testing, in compliance with the CLSI and EUCAST standards, with 3 months shelf life at present.
The AD Fosfomycin panel comprises 12 wells, containing the antibiotic incorporated into an agar medium in different concentrations, i.e. 11 two-fold dilutions (0.25-256 μg/mL).
The AD Fosfomycin 0.25-256 panel is the first of a series of agar dilution panels, which will be available as both standard and custom versions, in terms of antibiotics and concentrations.
This kit is needed to adapt the LC480 detection format to the probes that are used in FTD multiplexes to avoid crosstalk between channels.
